2026-01-09 21:44:07

CGON is a rare pre-IPO US biotech company I participated in. Recently, they announced the early release of Phase III clinical data, and the market reaction was a straight limit-up. The stock price has just broken through a new all-time high, and I am still holding. To be honest, why did the stock surge so high after the early announcement? I’m a bit confused myself. However, opportunities and risks often go hand in hand — if the data surprises negatively, a significant pullback is expected. So this position has both profit expectations and the readiness to endure setbacks. Investing is not gambling, but it does require the courage to take on risks.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

12 Likes

Reward
12
8
Repost
Share

Comment

0/400

GasFeeCryer

· 11h ago

Releasing data in advance can lead to such a strong rally? I really can't understand the logic behind biotech stocks, but since they dare to break new highs, it shows the market is still buying in. As for the risks, you're right; mental preparedness is the most important.

View OriginalReply0

DarkPoolWatcher

· 21h ago

Haha, once this data is out, the market gets excited. Hitting the daily limit is normal but can definitely get people hyped up.

View OriginalReply0

GasFeeCryBaby

· 01-09 22:02

The data was announced in advance, leading to a direct limit-up. This move is indeed a bit outrageous haha, it feels like the market has been waiting for this moment.

View OriginalReply0

RektButSmiling

· 01-09 21:58

Releasing data in advance to directly hit the daily limit-up—this pace is truly outrageous. But biotech stocks are like this: once the data is out, they either skyrocket or crash to the ground, with no middle ground.

View OriginalReply0

RugpullTherapist

· 01-09 21:56

Positive data just leads to a single limit-up; this round of market movement is indeed a bit outrageous... But biotech stocks are just like this; sometimes the market is simply irrational.

View OriginalReply0

CodeAuditQueen

· 01-09 21:54

The third phase data was announced in advance and directly hit the daily limit. This logical flaw is really big... It's just a bubble driven by market sentiment, with no underlying safety mechanism to anchor real value. After reaching a new historical high, just wait and see.

View OriginalReply0

DevChive

· 01-09 21:52

The data release directly hit the daily limit, this wave is indeed a bit fierce, but don't get too excited. Biotechnology stocks are like that; one bad news can cut them in half.

View OriginalReply0

RektCoaster

· 01-09 21:50

Good data leads to limit-ups; I really can't understand this logic... But if you make a profit, don't ask why, right? We'll deal with the risks when they come.

View OriginalReply0